A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.
复制标题
DOI:
10.1126/science.1212728
复制
发表时间:
2012-01-20
期刊:
影响因子:
--
通讯作者:
Westbrook TF
中科院分区:
文献类型:
--
作者:
Kessler JD;Kahle KT;Sun T;Meerbrey KL;Schlabach MR;Schmitt EM;Skinner SO;Xu Q;Li MZ;Hartman ZC;Rao M;Yu P;Dominguez-Vidana R;Liang AC;Solimini NL;Bernardi RJ;Yu B;Hsu T;Golding I;Luo J;Osborne CK;Creighton CJ;Hilsenbeck SG;Schiff R;Shaw CA;Elledge SJ;Westbrook TF
Myc is an oncogenic transcription factor frequently dysregulated in human cancer. To identify pathways supporting the Myc oncogenic program, we employed a genome-wide RNAi screen for Myc-synthetic-lethal genes and uncovered a role for the SUMO-activating-enzyme (SAE1/2). Loss of SAE1/2 enzymatic activity drives synthetic lethality with Myc. Inactivation of SAE2 leads to mitotic catastrophe and cell death selectively upon Myc hyper-activation. Mechanistically, SAE2 inhibition switches a transcriptional subprogram of Myc from activated to repressed. A subset of these SUMOylation-dependent-Myc-switchers (SMS genes) is required for mitotic spindle function and to support the Myc oncogenic program. SAE2 is required for Myc-dependent tumor growth, and patient survival significantly correlates with SAE1/SAE2 levels in Myc-high tumors. These studies reveal a mitotic vulnerability of Myc-driven cancers, demonstrate that inhibiting sumoylation impairs Myc-dependent tumorigenesis, and suggest inhibiting SUMOylation may have therapeutic benefits for patients with Myc-driven cancer.
登录
查看更多内容
影响因子:
11.2
作者:
Schmidt, Marcus;Boehm, Daniel;Gehrmann, Mathias
通讯作者:
Gehrmann, Mathias
影响因子:
64.8
作者:
Lowe, SW;Cepero, E;Evan, G
通讯作者:
Evan, G
影响因子:
64.5
作者:
Joukov, Vladimir;Groen, Aaron C.;Livingston, David M.
通讯作者:
Livingston, David M.
影响因子:
8.8
作者:
Deming SL;Nass SJ;Dickson RB;Trock BJ
通讯作者:
Trock BJ
影响因子:
56.9
作者:
HERMEKING, H;EICK, D
通讯作者:
EICK, D